Published in final edited form as:

Tetrahedron. 2009 September 19; 65(38): 7915–7920. doi:10.1016/j.tet.2009.07.079.

Synthesis of Boranoate, Selenoate, and Thioate Analogs of AZTp₄A and Ap₄A

Qianwei Han^a, Stefan G. Sarafianos^b, Eddy Arnold^{a,c}, Michael A. Parniak^d, Barbara L. Gaffney^a, and Roger A. Jones^a

^aDepartment of Chemistry and Chemical Biology, 610 Taylor Road, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, USA

^bDepartment of Molecular Microbiology & Immunology, University of Missouri School of Medicine, Columbia MO 65211-7310, USA

^cCenter for Advanced Biotechnology and Medicine, Piscataway, New Jersey 08854, USA

^dDepartment of Molecular Genetics & Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA

Abstract

We report efficient, one-flask procedures for the synthesis of a family of fourteen analogs of AZTp₄A and Ap₄A containing BH₃, S, or Se, along with two bisphosphonate analogs of Ap₄A. These compounds should slow unwanted enzymatic hydrolysis and have the potential to create unique binding interactions in biochemical and structural studies of the excision reaction responsible for resistance of HIV-1 to AZT, as well as assist in drug design.

Keywords

AZT; dinucleoside tetraphosphate; HIV- RT; boronoate

Introduction

Resistance by human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) to the nucleoside inhibitor 3'-azido-3'-deoxythymidine (AZT) has been a serious problem for many years.¹⁻³ After the chain-terminating AZT is incorporated into the DNA strand, it can be excised through nucleophilic attack by cellular adenosine triphosphate (ATP), thereby unblocking the DNA while creating the dinucleoside tetraphosphate, 5'-5'''-AZTp₄A.^{4,5} This excision occurs at the catalytic center of RT, where mutations that are known to enhance this reaction create a new hydrophobic pocket that binds the adenine ring of ATP. AZTp₄A has recently been shown to be a potent chain terminating inhibitor of RT, and mutant RTs that had become AZT-resistant showed stronger inhibition of excision than wild-type RT.⁶ Because RT

© 2009 Elsevier Ltd. All rights reserved.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supporting Information Available Spectra (UV, MS, and ¹H, ¹³C, ¹⁹F, and ³¹P NMR) for **6-13** and **16**. This material can be found online at:

continues to mutate with chronic drug treatment, a continuing stream of new drug candidates is needed, and the AZTp₄A analogs described here may provide useful therapeutic leads.

As part of our program in developing new synthetic methods for dinucleoside polyphosphates and their analogs,^{7,8} we now report the synthesis of a series of AZTp_xpppA analogs, **6-8**, containing a single modified phosphate adjacent to the AZT: both diastereomers of a boranoate, **6**, a thioate, **7**, and a selenoate, **8**, as well as **16** with a thioate adjacent to the adenosine. We had previously described a series of related hydrolysis-resistant analogs with thioates adjacent to each nucleoside and a methylene or difluoromethylene in place of the central phosphate.⁸ Preliminary experiments, however, suggest that analogs with bisphosphonates do not appear to be substrates for HIV-1 RT.⁹ Fourteen of the sixteen new compounds reported here retain the four bridging phosphate oxygen atoms that may be essential for coordination to Mg²⁺ ions in the RT active site, but represent a range of phosphate modifications adjacent to the AZT that might result in improved inhibition. We also report the related Ap_xpppA analogs. These compounds were important in defining the stereochemistry of the AZTp_xpppA analogs, as described below, and are of interest themselves because Ap₄A has been proposed as a signaling and regulatory molecule for many biological functions.¹⁰

Results and Discussion

Nucleic acid boranophosphates were pioneered by Shaw,¹¹ and they are receiving increasing attention for therapeutics and diagnostics.¹²⁻¹⁴ Thiophosphates are well known to display altered interactions with other species, including metals.¹⁵ Selenophosphates¹⁶ are less well known, but have recently been used for nucleic acid structure determination.¹⁷ Eckstein originally reported the synthesis of nucleoside triphosphates and α -thio-nucleoside triphosphates by hydrolysis or sulfurization, respectively, of a trimetaphosphate intermediate.¹⁸ Shaw later modified this method to prepare α -borano-nucleoside triphosphates,¹⁹ and more recently, α -thio, seleno-, and borano-nucleoside diphosphates.²⁰ α -Borano- and seleno-nucleoside triphosphates containing further modifications have also been made using trimetaphosphate intermediates.²¹⁻²³ In our original method for synthesis of unmodified dinucleoside tetraphosphates,⁷ a protected nucleoside (**1**) was phosphitylated with 2-chloro-4*H*-1,3,2-benzodioxaphosphorin-4-one in DMF to give **2** (Scheme 1). This intermediate was then reacted with pyrophosphate as the tri-*n*-butyl ammonium salt to form **3**, followed by oxidation with I₂/H₂O to give the trimetaphosphate (**4**), a sequence first described by Eckstein.¹⁸ Instead of subsequent hydrolysis as in Eckstein's method, we then added a nucleoside 5'-monophosphate (**5**) in DMF with ZnCl₂ as a catalyst to give unmodified dinucleoside tetraphosphates in 50-85% yields after removal of the protecting groups.

We report here a series of 16 modified dinucleoside tetraphosphates, listed in Table 1, that were made by expanding our approach as shown in Scheme 1 and described below. Synthetic procedures are detailed in the Experimental Section with full spectral characterizations for all compounds given in the Supporting Information.

Boranoates, thioates, and selenoates

As originally described by Eckstein,¹⁸ the oxidation of **3** can employ elemental sulfur (S₈) rather than I₂/H₂O. The resulting sulfurized trimetaphosphate (**4**, W=S) is stable in the absence of water, and we find that it reacts readily with adenosine monophosphate (**5**, AMP) in good yield to form a modified dinucleoside tetraphosphate with a single thiophosphate adjacent to the nucleoside derived from the trimetaphosphate, AZT. By this method, we have obtained AZTp_spppA (**7**) in 75% yield. We are able to completely separate the two diastereomers by reverse-phase chromatography and identify their stereochemistry, as described in a later section. The analog AZTp_spppA (**16**), was made by oxidation of **3** using a minimal amount of I₂/H₂O, followed by coupling with adenosine H-phosphonate (**14**) and sulfurization.

We have found that we can introduce Se or a BH₃ by a similar reaction of the AZT trimetaphosphate (**3**), although the reaction requires longer time. The selenization step using elemental selenium²⁰ in toluene requires 7 h, and subsequent reaction with AMP gives AZTp_{Se}pppA (**8**) in 57% yield. Boronation using a borane-*N,N*-diisopropylethylamine complex (BH₃·DIPEA)^{19,21,22} requires 16 h, even with 17 equiv of reagent. Subsequent reaction with AMP gives AZTp_{BH₃}pppA (**6**) in 66% yield. Reaction of the boranoated trimetaphosphate (**4**) with AMP appears to give better results using MgCl₂ as a catalyst compared to ZnCl₂, while the other trimetaphosphates all give higher yields with ZnCl₂. We have separated the diastereomers in each set by reverse-phase chromatography.

The retention times on reverse-phase chromatography for these tetraphosphates with single modifications increase in the order O<S<Se~BH₃. Further, the ³¹P NMR resonances of the modified phosphorus atoms move downfield in the order O (~ -11 ppm) < Se (~ 34 ppm) < S (~ 43 ppm) < BH₃ (~ 87-80 ppm), with the boranoate phosphorus resonances being quadrupole-broadened.

The boranoates may be of particular interest, since in general, they are known to display greater resistance to hydrolysis by cellular enzymes than thioates.¹¹ Because the borano group is isoelectronic with oxygen and pseudoisoelectronic with sulfur, it is negatively charged like phosphates and thioates. However, its properties are altered in several ways. It does not have lone pairs of electrons that can participate in hydrogen bonding or metal interactions; it increases hydrophobicity; and the P-B bond is less polarized than P-O and P-S bonds.¹¹ Canard has shown that the *R* diastereomer (shorter retention time) of α -borano-AZT triphosphate not only inhibits reverse transcription, but also decreases the excision rate.¹³ A group from Biota, Inc. extended this work by synthesizing α -borano- β,γ -difluoromethylene-AZT triphosphate. They showed that its *R* diastereomer, but not the *S*, was as effective an RT inhibitor as *R*- α -borano-AZT triphosphate, while it had considerably more stability in serum and cell extracts.²² They found that the diastereomer with shorter retention time of α -seleno- β,γ -difluoromethylene-AZT triphosphate was a potent inhibitor of HIV-RT as well.²³

We have also made a series of Ap₄A analogs with a single boranoate, Ap_{BH₃}pppA (**9**) in 66% yield, thioate, Ap_spppA (**10**) in 66% yield, and selenoate, Ap_{Se}pppA (**11**) in 38% yield. A compilation of a number of Ap₄A analogs has recently been reported.²⁴ Blackburn had previously synthesized a large group of bisphosphonate analogs of Ap₄A.²⁵

Bisphosphonates

Analogues containing a central bisphosphonate, App_{CX₂}ppA (**12**, X=H; **13**, X=F), were made in similar fashion in good yields using either methylenediphosphonate (O₃PCH₂PO₃⁴⁻) or difluoromethylenediphosphonate (O₃PCF₂PO₃⁴⁻)²⁶ in place of pyrophosphate. This variation of the trimetaphosphate approach had previously been demonstrated for triphosphate analogs.²² The ³¹P NMR chemical shifts of the phosphonate resonances are ~8 ppm with CH₂ and ~-6 ppm with CF₂, compared to ~-22 ppm with oxygen (Supporting Information).

>Assignment of stereochemistry

We have assigned the configurations of the diastereomers based on their relative retention times on reverse-phase chromatography and, where possible, their relative susceptibility to hydrolysis by snake venom phosphodiesterase. Eckstein had originally demonstrated that the *R* diastereomer of α -thioadenosine triphosphate was cleaved significantly faster than the *S* diastereomer.²⁷ Further, he found that the *R* diastereomer had a longer retention time on reverse-phase HPLC. Blackburn and McLennan used this selective enzymatic hydrolysis approach to assign configurations of the three diastereomers of Ap_{SPCH₂}pppA.²⁸ Canard has used X-ray crystallography to determine the absolute configuration of α -boranothymidine

diphosphate complexed with nucleoside diphosphate kinase,¹³ and Shaw has correlated this assignment with relative retention time.²⁹ Because the group priorities around the chiral phosphorus of a boranophosphate are opposite of those around thiophosphates, the designation of *R* and *S* are reversed for a given absolute configuration in these two families of analogs. Thus the *R* diastereomer of α -boranothymidine diphosphate has a shorter retention time than the *S* version.²⁹ Shaw²⁰ and the Biota Inc. group²² have used this correlation of retention time and stereochemistry to make strong arguments for assignments of other boranoate and selenoate analogs.

The monosubstituted analogs containing AZT (**6-8** and **16**) all gave poorly resolved chromatograms upon enzymatic digestion with snake venom phosphodiesterase due to the broad peak of phosphorylated AZT. Therefore, for these cases we have assigned the configurations of their diastereomers based on retention time. For the thioates (**7** and **16**) as well as the selenoate (**8**) we assign the diastereomers that elute first on both analytical and preparative reverse phase chromatography (listed first in Table 1), as *S*. For the boranoate (**6**) the diastereomer that elutes first (listed first in Table 1) has the same absolute configuration as the *S* thioates/selenates but is assigned *R*, because of the opposite priorities of boron with respect to sulfur/selenium, as described above.

The assignments described above were strongly supported by enzymatic degradation results for the closely related monosubstituted analogs of Ap₄A (**9-11**) which gave sufficient resolution of intermediates on analytical HPLC to allow the cleavage to be monitored. We digested 0.63 mM samples of each diastereomer of **9-11** with 0.2 mg of snake venom phosphodiesterase. These compounds were all quickly cleaved at their unmodified outer phosphates to form modified adenosine triphosphates that retained the chiral center at the α modifications. For these cases, we plotted the % triphosphate remaining, determined by HPLC, as a function of time (Figure 1). The results were in agreement with the assignments based on HPLC retention time.

Conclusion

The syntheses we describe here, together with the routes we previously reported,^{7,8} complete our elaboration of a general and convenient one-flask approach to the preparation of dinucleoside tetraphosphates and analogs. At least some of these compounds will be useful in further study of the AZT excision reaction, signaling, and drug design.

Experimental Section

General Procedures

Methylenediphosphonic acid, 2-chloro-4*H*-1,3,2-benzodioxaphosphorin-4-one, tri-*n*-butylamine, adenosine monophosphate monohydrate, elemental selenium and borane-*N,N*-diisopropylethylamine complex were purchased from Aldrich. Elemental sulfur was purchased from J.T.Baker. AZT was obtained from Transgenomic. Bis(tri-*n*-butylammonium) pyrophosphate was prepared according to the procedure described by Eckstein,³⁰ bis(tri-*n*-butylammonium) difluoromethylenediphosphonate was prepared by the procedure reported by Boyle,³¹ and adenosine 5'-H-phosphonate was prepared by a procedure developed in the Jones Lab.³² The preparative reverse phase HPLC was performed on a PrepPak system with three Waters Delta-Pak PrepPak® cartridges (C18, 300Å, 40 mm × 100 mm, 15 µm) using acetonitrile and 0.1 M ammonium bicarbonate (pH 7.5) or water. The analytical samples were analyzed on a Waters Atlantis™ analytical column (C18 column, 100Å, 4.6 mm × 50 mm, 3.0 µm) using acetonitrile and 0.1 M triethylammonium acetate (TEAA) buffer (pH 6.8), and the flow rate is 1.0 mL/min.

NMR Spectra

The NMR spectra were acquired on Varian 300 or 400 spectrometers. The samples were all converted to the sodium form and dissolved in D₂O. The ¹H and ¹³C spectra were referenced to 3-(trimethylsilyl)-1-propane-sulfonic acid, sodium salt. Signals in the ¹³C spectra at 57.1, 21.8, 17.7 and 0.0 are from this standard. The ³¹P spectra were referenced to 10% phosphoric acid in D₂O. The ¹⁹F spectra were referenced to hexafluorobenzene. In the ¹H NMR spectra, water suppression diminishes the adjacent resonances. UV spectra were acquired on a Varian Cary 4000 or an Aviv 14 UV spectrophotometer, and the MS acquired on a Waters/Micromass Platform LCZ mass spectrometer.

[*R_P*] and [*S_P*] adenosine 3'-azido-3'-deoxythymidine 5',5'''-*P*¹,*P*⁴-(*P*⁴-borano)-tetraphosphate (6a,b)

To a solution of 3'-azido-3'-deoxythymidine (0.087 g, 0.33 mmol) in 2 mL of anhydrous *N,N*-dimethylformamide (DMF) was added 2-chloro-4*H*-1,3,2-benzo-dioxaphosphorin-4-one (0.106 g, 0.36 mmol, 1.1 equiv). The solution was stirred for 15 min at room temperature under N₂. A 0.5 M solution of bis(tri-*n*-butylammonium) pyrophosphate in anhydrous DMF (1.3 mL, 0.65 mmol, 2.0 equiv) was vortexed with tri-*n*-butylamine (0.60 mL, 2.5 mmol, 7.6 equiv) and immediately added to the reaction mixture. After 20 min, borane-*N,N*-diisopropylethylamine complex (1.0 mL, 5.8 mmol, 18 eq) was added. After 16 hr, adenosine monophosphate monohydrate, in the proton form (0.68 g, 1.9 mmol, 5.8 eq), was dissolved in a 40% tetrabutylammonium hydroxide aqueous solution (2.5 mL, 3.8 mmol, 12 eq), dried by evaporation of pyridine and DMF, and added to the reaction with stirring. Immediately MgCl₂(H₂O)₆ (0.40 g, 2.0 mmol, 5.9 eq) that had been dried by evaporation of pyridine and DMF was added. The reaction was stirred for 4 hr and then 20 mL of water was added. The resulting precipitate was removed by filtration, and the filtrate was washed with 3 × 30 mL of CH₂Cl₂. The aqueous solution was concentrated and applied to a column of sodium cation exchange resin (50WX2, 10 mL, 6.0 mmol). The mixture of two diastereomers was concentrated, purified, and separated by reverse-phase HPLC to give 0.11 g of [*R_P*]-**6a** (0.12 mmol, 36%) and 0.088 g of [*S_P*]-**6b** (0.098 mmol, 30%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with *m/z* (M-1) 833.37 for [*R_P*]-**6a** and 833.31 for [*S_P*]-**6b** (calculated for C₂₀H₃₀BN₁₀O₁₈P₄⁻: 833.08). [*R_P*]-**6a**: ³¹P NMR (D₂O, 121 MHz): δ 86.00-81.00 (br, 1P), (-)10.40-(-)11.07 (m, 1P), (-)21.75-(-)22.81 (m, 2P). [*S_P*]-**6b**: ³¹P NMR (D₂O, 121 MHz): δ 86.75-79.77 (br, 1P), (-)10.78-(-)11.15 (m, 1P), (-)22.36-(-)23.13 (m, 2P).

[*S_P*] and [*R_P*] adenosine 3'-azido-3'-deoxythymidine 5',5'''-*P*¹,*P*⁴-(*P*⁴-thio)-tetraphosphate (7a,b)

Starting with 3'-azido-3'-deoxythymidine (0.087 g, 0.33 mmol), intermediate **3** was prepared by the same procedure described for **6a,b**. After 20 min excess S₈ (0.037 g, 1.2 mmol, 3.6 eq) that had been dried by evaporation of pyridine and DMF was added. After 15 min, a mixture of AMP, in the proton form (0.44 g, 1.2 mmol, 3.6 equiv), and zinc chloride (0.43 g, 3.2 mmol, 9.7 equiv) that had been dried together by evaporation of pyridine and DMF was added with stirring. After 16 h, 10% aqueous ammonia (20 mL, 118 mmol) was added, and the precipitated sulfur was removed by filtration. The basic filtrate was applied to a column of sodium cation exchange resin (50WX2, 10 mL, 6.0 mmol) to remove Zn²⁺. The eluate was concentrated and the two diastereomers were purified and separated by reverse-phase HPLC to give 0.12 g of [*S_P*]-**7a** (0.13 mmol, 39%) and 0.11 g of [*R_P*]-**7b** (0.12 mmol, 36%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with *m/z* (M-1) 851.54 for [*S_P*]-**7a** and 851.54 for [*R_P*]-**7b** (calculated for C₂₀H₂₇N₁₀O₁₈P₄S⁻: 851.02). [*S_P*]-**7a**: ³¹P NMR (D₂O, 121 MHz): δ 43.29 (d, *J* = 24.33 Hz, 1P), -10.98 (d, *J* = 18.07 Hz, 1P), -22.74 (t, *J* = 17.35 Hz, 1P), -23.68 (dd, *J* = 24.32 Hz, *J* = 16.44 Hz, 1P). [*R_P*]-**7b**: ³¹P NMR (D₂O,

121 MHz): δ 43.20 (d, J = 25.87 Hz, 1P), -10.97 (d, J = 18.07 Hz, 1P), -22.73 (t, J = 17.33 Hz, 1P), -23.71 (dd, J = 25.80 Hz, J = 16.45 Hz, 1P).

[Sp] and [Rp] adenosine 3'-azido-3'-deoxythymidine 5',5'''-P¹, P⁴-(P⁴-seleno)-tetraphosphate (8a,b)

Starting with 3'-azido-3'-deoxythymidine (0.081 g, 0.30 mmol), **8a,b** was prepared by the same procedure described for **7a,b**, except that a dry solution of Se (0.072 g, 0.91 mmol, 3.0 eq) in 30 mL of toluene was used to oxidize **3** (7 hr) instead of S₈. The reaction solution was concentrated to remove toluene before the ammonia treatment (20 mL, 118 mmol) and was filtered to remove excess Se after the ammonia treatment. The mixture of two diastereomers was concentrated, purified, and separated by reverse-phase HPLC to give 0.085 g of [Sp]-**8a** (0.088 mmol, 29%) and 0.082 g of [Rp]-**8b** (0.085 mmol, 28%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with m/z (M-1) 899.34 for [Sp]-**8a** and 899.47 for [Rp]-**8b** (calculated for C₂₀H₂₇N₁₀O₁₈P₄Se⁻: 898.96). ³¹P NMR (D₂O, 121 MHz): δ 33.73 (d, J = 28.70 Hz, 1P), -10.98 (d, J = 18.27 Hz, 1P), -22.73 (t, J = 17.08 Hz, 1P), -24.18 (dd, J = 29.07 Hz, J = 16.32 Hz, 1P). [Rp]-**8b**: ³¹P NMR (D₂O, 121 MHz): δ 33.64 (d, J = 31.09 Hz, 1P), -10.98 (d, J = 18.19 Hz, 1P), -22.77 (t, J = 17.31 Hz, 1P), -24.25 (dd, J = 31.08 Hz, J = 16.57 Hz, 1P).

[Rp] and [Sp] diadenosine-5',5'''-P¹, P⁴-(P¹-borano)-tetraphosphate (9a,b)

Starting with 2',3'-O-6-*N*-triacetyladenosine (0.12 g, 0.30 mmol), **9a,b** was prepared by the same procedure described for **6a,b**. The two diastereomers were purified and separated by reverse-phase HPLC to give 0.11 g of [Rp]-**9a** (0.12 mmol, 40%) and 0.070 g of [Sp]-**9b** (0.078 mmol, 26%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with m/z (M-1) 833.37 for [Rp]-**9a** and 833.31 for [Sp]-**9b** (calculated for C₂₀H₃₀BN₁₀O₁₈P₄⁻: 833.08). ³¹P NMR (D₂O, 121 MHz): δ 86.03-80.61 (br, 1P), $(-10.54-(-11.16$ (m, 1P), $(-22.24-(-23.15$ (m, 2P). [Sp]-**9b**: ³¹P NMR (D₂O, 121 MHz): δ 86.54-81.39 (br, 1P), $(-10.61-(-11.26$ (m, 1P), $(-22.30-(-23.10$ (m, 2P).

[Sp] and [Rp] diadenosine-5',5'''-P¹, P⁴-(P¹-thio)-tetraphosphate (10a,b)

Starting with 2',3'-O-6-*N*-triacetyladenosine (0.13 g, 0.33 mmol), **10a,b** was prepared by the same procedure described for **7a,b**. The two diastereomers were purified and separated by reverse-phase HPLC to give 0.11 g of [Sp]-**10a** (0.12 mmol, 36%) and 0.094 g of [Rp]-**10b** (0.10 mmol, 30%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with m/z (M-1) 851.48 for [Sp]-**10a** and 851.41 for [Rp]-**10b** (calculated for C₂₀H₂₇N₁₀O₁₈P₄S⁻: 851.02). [Sp]-**10a**: ³¹P NMR (D₂O, 121 MHz): δ 43.67 (d, J = 25.3 Hz, 1P), -10.85 (d, J = 17.8 Hz, 1P), -22.60 (t, J = 17.1 Hz, 1P), -23.62 (dd, J = 25.3 Hz, J = 16.5 Hz, 1P). [Rp]-**10b**: ³¹P NMR (D₂O, 121 MHz): δ 43.51 (d, J = 25.1 Hz, 1P), -10.97 (d, J = 18.1 Hz, 1P), -22.74 (t, J = 17.4 Hz, 1P), -23.67 (dd, J = 25.0 Hz, J = 16.7 Hz, 1P).

[Sp] and [Rp] diadenosine-5',5'''-P¹, P⁴-(P¹-seleno)-tetraphosphate (11a,b)

Starting with 2',3'-O-6-*N*-triacetyladenosine (0.12 g, 0.30 mmol), **11a,b** was prepared by the same procedure described for **8a,b**. The two diastereomers were purified and separated by reverse-phase HPLC to give 0.060 g of [Sp]-**11a** (0.062 mmol, 21%) and 0.050 g of [Rp]-**11b** (0.052 mmol, 17%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with m/z (M-1) 899.28 for [Sp]-**11a** and 899.60 for [Rp]-**11b** (calculated for C₂₀H₃₀BN₁₀O₁₈P₄⁻: 898.96). [Sp]-**11a**: ³¹P NMR (D₂O, 121 MHz): δ 33.92 (d, J = 30.0 Hz, 1P), -10.93 (d, J = 18.0 Hz, 1P), -22.80 (t, J = 17.4 Hz, 1P), -24.31 (dd, J = 30.1 Hz, J = 16.8 Hz, 1P). [Rp]-**11b**: ³¹P NMR (D₂O, 121 MHz): δ 33.90 (d, J = 30.4 Hz, 1P), -11.00 (d, J = 18.2 Hz, 1P), -22.54 (t, J = 17.5 Hz, 1P), -24.34 (dd, J = 30.4 Hz, J = 16.9 Hz, 1P).

Diadenosine-5',5'''-P¹,P⁴-(P²,P³-methylene)-tetraphosphate (12)

To a solution of 2',3'-O-6-*N*-triacetyladenosine (0.12 g, 0.30 mmol) in 2 mL of anhydrous DMF was added 2-chloro-4*H*-1,3,2-benzo-dioxaphosphorin-4-one (0.12 g, 0.59 mmol, 2.0 equiv). The solution was stirred for 15 min at room temperature under N₂. Tri-*n*-butylamine (0.60 mL, 2.5 mmol, 8.3 equiv) and methylenediphosphonic acid (0.073 g, 0.41 mmol, 1.4 equiv) were added. After 20 min, a solution of iodine (0.18 g, 0.70 mmol, 2.3 equiv) in 1.5 mL of pyridine and 0.01 mL of water was added. After 15 min, a mixture of AMP, in the proton form (0.39 g, 1.1 mmol, 3.7 equiv), and zinc chloride (0.44 g, 3.2 mmol, 11 equiv) that had been dried together by evaporation of pyridine and DMF was added with stirring. After 20 h, 10% aqueous ammonia (20 mL, 118 mmol) was added, and the deprotection was complete after 1 h. The dilute basic solution was applied to a column of sodium cation-exchange resin (50WX2, 10 mL, 6.0 mmol) to remove Zn²⁺. The product was concentrated and purified by reverse-phase HPLC to give 0.22 g of **12** as the ammonium salt (0.24 mmol, 80%). LC-MS in negative mode, with *m/z* (M-1) 833.24 (calculated for C₂₁H₂₉N₁₀O₁₈P₄⁻: 833.06). ³¹P NMR (D₂O, 121 MHz): δ 8.33 (d, *J* = 25.6 Hz, 2P), -10.41 (d, *J* = 25.5 Hz, 2P).

Diadenosine-5',5'''-P¹,P⁴-(P²,P³-difluoromethylene)-tetraphosphate (13)

Starting with 2',3'-O-6-*N*-triacetyladenosine (0.13 g, 0.33 mmol), **13** was prepared by the same procedure described for **12**, except that a 0.2 M solution of bis(tri-*n*-butylammonium) difluoromethylenediphosphonate in anhydrous DMF (3.0 mL, 0.60 mmol, 1.8 equiv) was vortexed with tri-*n*-butylamine (0.60 mL, 2.5 mmol, 7.6 equiv) and immediately added to the reaction mixture of **2** to make intermediate **3**, instead of adding tri-*n*-butylamine and methylenediphosphonic acid. The product was purified by reverse-phase HPLC to give 0.25 g of **13** as the ammonium salt (0.27 mmol, 82%). LC-MS in negative mode, with *m/z* (M-1) 869.65 (calculated for C₂₁H₂₇F₂N₁₀O₁₈P₄⁻: 869.04). ³¹P NMR (D₂O, 121 MHz): δ -5.90 (tm, *J* = 82.8 Hz, 2P), (-) 10.12-(-)11.02 (m, 2P).

[S_P] and [R_P] adenosine 3'-azido-3'-deoxythymidine 5',5'''-P¹,P⁴-(P¹-thio)-tetraphosphate (16a,b)

To a solution of 3'-azido-3'-deoxythymidine (0.081 g, 0.30 mmol) in 2 mL of anhydrous DMF was added 2-chloro-4*H*-1,3,2-benzo-dioxaphosphorin-4-one (0.078 g, 0.39 mmol, 1.3 equiv). The solution was stirred for 15 min at room temperature under nitrogen. A 0.5 M solution of bis(tri-*n*-butylammonium) pyrophosphate in anhydrous DMF (1.3 mL, 0.65 mmol, 2.2 equiv) was vortexed with tri-*n*-butylamine (0.60 mL, 2.5 mmol, 8.3 equiv) and immediately added to the reaction mixture. After 20 min a solution of iodine (0.092 g, 0.36 mmol, 1.2 equiv) in 2.0 mL of pyridine and 0.01 mL of water was added. After 15 min, a mixture of 0.16 M of adenosine 5'-H-phosphonate, **14**, in the tri-*n*-butylammonium form (6.0 mL, 0.96 mmol, 3.2 equiv), S₈ (0.056 g, 1.7 mmol, 5.7 equiv) and zinc chloride (0.36 g, 2.64 mmol, 8.8 equiv) that had been dried together by evaporation of pyridine and DMF was added with stirring. After 21 hr, 10% aqueous ammonia (20 mL, 118 mmol) was added to keep the zinc in solution, and the dilute basic solution was washed with methylene chloride to remove the excess sulfur and DMF, and then applied to a column of sodium cation exchange resin (50WX2, 10 mL, 6.0 mmol, 20 equiv) to remove Zn²⁺. The product was concentrated and purified by preparative reverse-phase HPLC using 0.1 M ammonium bicarbonate in acetonitrile to give 0.094 g of [S_P]-**16a** (0.10 mmol, 33%) and 0.12 g of [R_P]-**16b** (0.13 mmol, 43%) as the ammonium salts. The products eluted in the order listed. LC-MS in negative mode, with *m/z* (M-1) 851.40 for [S_P]-**16a** and 851.46 for [R]-**16b** (calculated for C₂₀H₂₇N₁₀O₁₈P₄S⁻: 851.02). [S_P]-**16a**: ³¹P NMR (D₂O, 162 MHz): δ 44.32 (d, *J* = 25.7 Hz, 1P), -10.57 (d, *J* = 17.6 Hz, 1P), -21.94 (t, *J* = 16.8 Hz, 1P), -23.00 (dd, *J* = 25.7 Hz, *J* = 16.1 Hz, 1P). [R_P]-**16b**: ³¹P NMR (D₂O, 162 MHz): δ 44.18 (d, *J* = 26.0 Hz, 1P), -10.59 (d, *J* = 17.9 Hz, 1P), -22.00 (t, *J* = 17.3 Hz, 1P), -23.00 (dd, *J* = 25.9 Hz, *J* = 16.4 Hz, 1P).

Identification of Configurations of the Diastereomers of Ap_{BH₃}pppA (9a,b), Ap_SpppA (10a,b) and Ap_{Se}pppA (11a,b)

To a solution of 0.32 μmol of one diastereomer from each pair in 500 μL of 100 mM Tris•HCl buffer (pH = 8.7), 2 mM MgCl₂, was added 4 μL of snake venom phosphodiesterase in water (50 μg/μL, Type IV from *Crotalus atrox*). The solution was maintained at 37°C and analyzed by LC-MS (20 μL each time, λ = 280 nm) after various time intervals. The percentages of Ap_Wppp (W = BH₃, S or Se) (relative to the total nucleoside-containing peaks) were monitored and plotted against time (Fig. 1-3). The other diastereomer was assayed following the same procedure.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH grants GM066671 and GM079760.

References and notes

1. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. *Biochemistry* 1998;37:15908–15917. [PubMed: 9843396]
2. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. *J. Virol* 2001;75:7202–7205. [PubMed: 11435603]
3. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. *J. Mol. Biol* 2009;385:693–713. [PubMed: 19022262]
4. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. *J. Virol* 2001;75:4832–4842. [PubMed: 11312355]
5. Meyer PR, Matsuura SE, So AG, Scott WA. *Proc. Natl. Acad. Sci. USA* 1998;95:13471–13476. [PubMed: 9811824]
6. Dharmasena S, Pongracz Z, Arnold E, Sarafianos SG, Parniak MA. *Biochemistry* 2007;46:828–836. [PubMed: 17223704]
7. Han Q, Gaffney BL, Jones RA. *Org. Lett* 2006;8:2075–2077. [PubMed: 16671785]
8. Han Q, Sarafianos SG, Arnold E, Parniak MA, Gaffney BL, Jones RA. *Org. Lett* 2007;9:5243–5246. [PubMed: 17988141]
9. Parniak, M. manuscript in preparation
10. McLennan AG, Barnes LD, Blackburn GM, Brenner C, Guranowski A, Miller AD, Rovira JM, Rotllan P, Soria B, Tanner JA, Sillero A. *Drug Devel Research* 2001;52:249–259.
11. Li P, Sergueeva Z, Dobrikov M, Shaw B. *Chem. Rev* 2007;107:4746–4796. [PubMed: 17967037]
12. Li P, Dobrikov M, Liu H, Shaw BR. *Org. Lett* 2003;5:2401–2403. [PubMed: 12841740]
13. Meyer P, Schneider B, Sarfati S, Deville-Bonne D, Guerreiro C, Boretto J, Janin J, Veron M, Canard B. *The EMBO Journal* 2000;19:3520–3529. [PubMed: 10899107]
14. McCuen HB, Noe MS, Sierzchala AB, Higson AP, Caruthers MH. *J. Am. Chem. Soc* 2006;128:8138–8139. [PubMed: 16787069]
15. Eckstein F. *Biochemie* 2002;84:841–848.
16. Stec WJ, Zon G, Egan W, Stec B. *J. Am. Chem. Soc* 1984;106:6077–6079.
17. Salon J, Sheng J, Jiang J, Chen G, Caton-Williams J, Huang Z. *J. Am. Chem. Soc* 2007;129:4862–4863. [PubMed: 17388591]
18. Ludwig J, Eckstein F. *J. Org. Chem* 1989;54:631–635.
19. Krzyzanowska BK, He K, Hasan A, Shaw BR. *Tetrahedron* 1998;54:5119–5128.
20. Li P, Xu Z, Liu H, Wennefors CK, Dobrikov MI, Ludwig J, Shaw BR. *J. Am. Chem. Soc* 2005;127:16782–16783. [PubMed: 16316213]

21. Boyle NA, Rajwanshi VK, Prhac M, Wang G, Fagan P, Chen F, Ewing GJ, Brooks JL, Hurd T, Leeds JM, Bruice TW, Cook PD. *J. Med. Chem* 2005;48:2695–2700. [PubMed: 15801860]
22. Wang G, Boyle N, Chen F, Rajappan V, Fagan P, Brooks JL, Hurd T, Leeds JM, Rajwanshi VK, Jin Y, Prhac M, Bruice TW, Cook PD. *J. Med. Chem* 2004;47:6902–6913. [PubMed: 15615539]
23. Boyle NA, Fagan P, Brooks JL, Prhac M, Lambert J, Cook PD. *Nucleosides Nucleotides Nucl. Acids* 2005;24:1651–1664.
24. Guranowski A. *Acta Biochim. Pol* 2003;50:947–972. [PubMed: 14739989]
25. McLennan AG, Taylor GE, Prescott M, Blackburn GM. *Biochemistry* 1989;28:3868–3875. [PubMed: 2546583]
26. Boyle NA. *Org. Lett* 2006;8:187–189. [PubMed: 16408871]
27. Burgers PMJ, Eckstein F. *Proc. Natl. Acad. Sci. USA* 1978;75:4798–4800. [PubMed: 368798]
28. Blackburn GM, Taylor GE, Thatcher GRJ, Prescott M, McLennan AG. *Nucleic Acids Res* 1987;15:6991–7004. [PubMed: 2821489]
29. Li P, Shaw BR. *J. Org. Chem* 2004;69:7051–7057. [PubMed: 15471452]
30. Ludwig J, Eckstein F. *J. Org. Chem* 1989;54:631–635.
31. Boyle NA. *Organic Letters* 2006;8:187–189. [PubMed: 16408871]
32. Han Q, Sarafianos SG, Arnold E, Parniak MA, Gaffney BL, Jones RA. *Organic Letters* 2007;9:5243–5246. [PubMed: 17988141]

Scheme 1. Synthesis of AZTp₄A and Ap₄A AnalogsA = adenine; B = adenine or thymine; W = BH₃ or S or Se or O; X = N₃ or OH; Y = H or OH;Z = O or CH₂ or CF₂

Figure 1.
Disappearance of $\text{Ap}_{\text{BH}_3}\text{pp}$ with Enzymatic Degradation of $\text{Ap}_{\text{BH}_3}\text{pppA}$ (9)

Figure 2.
Disappearance of Ap_Spp with Enzymatic Degradation of Ap_SpppA (10)

Figure 3.
Disappearance of $\text{Ap}_{\text{Se}}\text{pp}$ with Enzymatic Degradation of $\text{Ap}_{\text{Se}}\text{pppA}$ (11)

Table 1

Analogues of AZTp₄A and Ap₄A

	B	X	Y	Z	W	%*	%**
[R]-6a	T	N ₃	H	O	BH ₃	36	66
[S]-6b	T	N ₃	H	O	BH ₃	30	
[S]-7a	T	N ₃	H	O	S	39	75
[R]-7b	T	N ₃	H	O	S	36	
[S]-8a	T	N ₃	H	O	Se	29	57
[R]-8b	T	N ₃	H	O	Se	28	
[R]-9a	A	OH	OH	O	BH ₃	40	66
[S]-9b	A	OH	OH	O	BH ₃	26	
[S]-10a	A	OH	OH	O	S	36	66
[R]-10b	A	OH	OH	O	S	30	
[S]-11a	A	OH	OH	O	Se	21	38
[R]-11b	A	OH	OH	O	Se	17	
12	A	OH	OH	CH ₂	O	-	80
13	A	OH	OH	CF ₂	O	-	82
[S]-16a	T	N ₃	H	O	S	33	76
[R]-16b	T	N ₃	H	O	S	43	

A = adenine; T = thymine; %* = yield of individual diastereomer; %** = combined yield of both diastereomers